Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004–2014

Findings from a recent cohort study published in Diabetes Care (1), which included >740,000 individuals with type 2 diabetes (T2D) aged ≥65 years, demonstrated that both sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) were associated with smaller numbers of cardiovascular events and death than dipeptidyl peptidase 4 inhibitors (DPP-4i), with the largest benefits being seen among frail people. Adverse events that affected frailer individuals were not more common with SGLT2i or GLP-1RAs than with DPP-4i (1).


http://dlvr.it/T4cnLx

A Special Thanks to the Reviewers of Diabetes Care

Diabetes Care calls on thousands of scientific and medical experts each year to review manuscript submissions. The editors of Diabetes Care sincerely appreciate the efforts of all our reviewers who volunteer their time and expertise to provide valuable feedback to ensure the consistently high quality of the research published in each issue. We would like to recognize the “top” reviewers—based on the number of reviews completed, timeliness, reliability, and quality—for their outstanding contributions and dedication to Diabetes Care.


http://dlvr.it/T4cn1r